Lantern Pharma Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Lantern Pharma Inc. on January 12, 2023, reporting events occurring on the same date. The company is a Delaware corporation with its principal executive offices in Dallas, Texas, and its common stock trades on The Nasdaq Stock Market under the symbol LTRN.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on a specific executive compensation adjustment.
Material Changes
The Board of Directors approved an amendment to the employment agreement for Kishor G. Bhatia, Chief Scientific Officer. His annual base salary was increased to $235,000, effective with the first pay period in January 2023.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items beyond the salary adjustment noted above.
Key Facts for Investor Verification
- Effective date of the salary increase: January 2023.
- Executive affected: Kishor G. Bhatia, Chief Scientific Officer.
- New annual base salary: $235,000.
- Approval authority: Lantern Pharma Inc. Board of Directors.